Photocure ASA - Presentation of the 1st quarter 2010 report
Oslo, Norway, 26 April 2010
Photocure ASA will present its first quarter 2010 report on Wednesday April 28th 2010 at Shippingklubben, Haakon VIIs gate 1 (top floor), Oslo, Norway.
The presentation will begin at 17.00 and representatives from the company will be Kjetil Hestdal (President & CEO) and Christian Fekete (CFO).
The presentation is scheduled to conclude at 17.45 (CET).
The presentation will be publicly available at www.photocure.com. It will be possible to follow the presentation through a live webcast at Photocure's Internet pages.
Please register your attendance at Photocure ASA by Tuesday 27th of April at 15:00. Contact person: Grete Faye-Schjøll (e-mail: gfs@photocure.no / phone +47 22 06 22 10 / fax +47 22 06 22 18).
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing on a regional or global basis prior to phase III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM)platform.
For more information about Photocure, visit our website at www.photocure.com.
Photocure®, the Photocure logo and Hexvix® are registered trademarks of Photocure ASA.